Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com



Growth: Bad revenue growth rate -4.7%, there is slowdown compared to average historical growth rates 13.7%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of -15.6%

Profitability: LTM EBITDA margin is positive, +28.3%. On average the margin is decreasing unsteadily. Gross margin is high, +55.5%. In the last quarter the company beat the estimated EPS, +22.3%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.21 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 1.7%. Free cash flow yield 3.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 72.1% higher than minimum and 23.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.3x by EV / Sales multiple , the company can be 24.6% overvalued

Insiders: For the last 3 months insiders sold company shares on $7.3 mln (-0.004% of cap.)

Key Financials (Download financials)

Ticker: ABT  postmarket  107.26  (-0.8%)
Share price, USD:  (+0.1%)108.09
year average price 114.06  


year start price 132.47 2021-12-06

max close price 141.46 2021-12-27

min close price 95.06 2022-10-21

current price 108.09 2022-12-05
Common stocks: 1 750 939 953

Dividend Yield:  1.7%
FCF Yield LTM: 3.5%
EV / LTM EBITDA: 15.5x
EV / EBITDA annualized: 20.1x
Last revenue growth (y/y):  -4.7%
Last growth of EBITDA (y/y):  -30.5%
Historical revenue growth:  13.7%
Historical growth of EBITDA:  23.5%
EV / Sales: 4.4x
Margin (EBITDA LTM / Revenue): 28.3%
Fundamental value created in LTM:
Market Cap ($m): 189 259
Net Debt ($m): 7 823
EV (Enterprise Value): 197 082
Price to Book: 5.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF / Free Cash Flow ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

Website traffic (visits mln/month) abbott.com

Three months progress: -15.6%

News


2022-11-28Zacks Investment Research

Is Trending Stock Abbott Laboratories (ABT) a Buy Now?

2022-11-24Seeking Alpha

Abbott Laboratories: Good Execution And Attractive Valuation

2022-11-22The Motley Fool

Want Passive Income in 2023? Buy These Dividend Kings

2022-11-21Seeking Alpha

4 Growth Stocks To Buy As Inflation Cools

2022-11-21Seeking Alpha

Abbott Laboratories: Prepare For A Tough 2023

2022-11-18Zacks Investment Research

Abbott (ABT) Up 7.7% Since Last Earnings Report: Can It Continue?

2022-11-15Zacks Investment Research

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?

2022-11-10The Motley Fool

Better Buy: Johnson & Johnson vs. Abbott Laboratories

2022-11-04Zacks Investment Research

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

2022-11-01The Motley Fool

This Groundbreaking Device Just Keeps Winning for Abbott Labs
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2022 q3 2022 q2 2022 q1 2021 q4 2021 q3 2021 q2 2021 q1 2020 q4 2020 q3 2020 q2 2020 q1 2019 q4 2019 q3 2019 q2 2019 q1 2018 q4 2018 q3 2018 q2 2018 q1 2017 q4 2017 q3 2017 q2 2017 q1 2016 q4 2016 q3 2016 q2 2016 q1 2015 q4 2015 q3 2015 q2 2015 q1 2014 q4 2014 q3 2014 q2 2014 q1 2013 q4 2013 q3 2013 q2 2013 q1
date 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31
symbol ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1800.000 1800.000 1800.000 1800.000 1800.000 1800.000
fillingDate 2022-11-01 2022-08-02 2022-05-03 2022-02-18 2021-11-03 2021-08-04 2021-05-05 2021-02-19 2020-11-04 2020-07-29 2020-04-29 00:00:00 2020-02-21 00:00:00 2019-10-31 00:00:00 2019-07-31 2019-05-01 00:00:00 2019-02-22 00:00:00 2018-10-31 00:00:00 2018-08-01 00:00:00 2018-05-02 00:00:00 2018-02-16 00:00:00 2017-11-02 00:00:00 2017-08-02 00:00:00 2017-05-03 00:00:00 2017-02-17 00:00:00 2016-11-03 00:00:00 2016-08-03 2016-05-04 00:00:00 2016-02-19 00:00:00 2015-11-05 00:00:00 2015-08-04 00:00:00 2015-05-06 00:00:00 2015-02-27 2014-11-06 00:00:00 2014-08-05 00:00:00 2014-05-07 00:00:00 2014-02-21 2013-11-07 00:00:00 2013-08-06 00:00:00 2013-05-08 00:00:00
acceptedDate 2022-11-01 16:06:19 2022-08-02 16:02:47 2022-05-03 16:29:24 2022-02-18 16:02:57 2021-11-03 16:04:53 2021-08-04 16:01:33 2021-05-05 16:01:22 2021-02-19 16:10:04 2020-11-04 16:01:05 2020-07-29 17:16:23 2020-04-29 16:16:47 2020-02-21 16:28:23 2019-10-31 16:02:42 2019-07-31 16:15:28 2019-05-01 16:09:25 2019-02-22 16:13:21 2018-10-31 16:02:08 2018-08-01 16:02:04 2018-05-02 16:17:34 2018-02-16 16:04:37 2017-11-02 16:18:54 2017-08-02 16:16:39 2017-05-03 16:17:02 2017-02-17 16:17:24 2016-11-03 16:26:45 2016-08-03 16:32:32 2016-05-04 16:32:12 2016-02-19 15:48:41 2015-11-05 14:37:57 2015-08-04 16:28:00 2015-05-06 16:56:54 2015-02-27 12:57:49 2014-11-06 17:01:19 2014-08-05 16:32:05 2014-05-07 16:47:07 2014-02-21 17:16:35 2013-11-07 16:05:51 2013-08-06 12:33:40 2013-05-08 15:33:31
calendarYear 2022.000 2022.000 2022.000 2021.000 2021.000 2021.000
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
revenue 10 410M 11 257M 11 895M 11 468M 10 928M 10 223M 10 456M 10 701M 8 853M 7 328M 7 726M 8 314M 8 076M 7 979M 7 535M 7 765M 7 656M 7 767M 7 390M 7 589M 6 829M 6 637M 6 335M 5 333M 5 302M 5 333M 4 885M 5 188M 5 150M 5 170M 4 897M 5 290M 5 104M 5 551M 5 244M 5 655M 5 369M 5 446M 5 378M
costOfRevenue 4 629M 4 933M 4 987M 4 766M 4 423M 4 947M 4 401M 4 493M 3 966M 3 263M 3 281M 3 434M 3 358M 3 279M 3 160M 3 191M 3 166M 3 282M 3 067M 3 263M 2 857M 3 173M 3 044M 2 312M 2 285M 2 287M 2 140M 2 206M 2 242M 2 218M 2 081M 2 300M 2 331M 2 506M 2 470M 2 613M 2 451M 2 545M 2 432M
grossProfit 5 781M 6 324M 6 908M 6 702M 6 505M 5 276M 6 055M 6 208M 4 887M 4 065M 4 445M 4 880M 4 718M 4 700M 4 375M 4 574M 4 490M 4 485M 4 323M 4 326M 3 972M 3 464M 3 291M 3 021M 3 017M 3 046M 2 745M 2 982M 2 908M 2 952M 2 816M 2 990M 2 773M 3 045M 2 774M 3 042M 2 919M 2 901M 2 946M
grossProfitRatio 0.555 0.562 0.581 0.584 0.595 0.516 0.579 0.580 0.552 0.555 0.575 0.587 0.584 0.589 0.581 0.589 0.586 0.577 0.585 0.570 0.582 0.522 0.519 0.566 0.569 0.571 0.562 0.575 0.565 0.571 0.575 0.565 0.543 0.549 0.529 0.538 0.544 0.533 0.548
researchAndDevelopmentExpenses 782M 684M 697M 762M 672M 654M 654M 698M 580M 564M 578M 595M 596M 577M 672M 562M 574M 575M 589M 613M 562M 513M 547M 343M 352M 348M 379M 369M 378M 345M 313M 356M 307M 335M 387M 386M 357M 363M 346M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 2 570M 2 302M 2 276M 2 548M 2 413M 2 440M 2 434M 2 478M 2 359M 2 377M 2 466M 2 542M 2 462M 2 099M 2 132M 2 424M 1 609M 1 628M 1 737M 1 698M 1 655M 1 666M 1 727M 1 737M 1 644M 1 603M 1 788M 1 762M 1 701M 1 735M 1 714M 1 786M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2 731M 2 757M 2 787M 3 048M 2 767M 2 726M 2 783M 2 570M 2 302M 2 276M 2 548M 2 413M 2 440M 2 434M 2 478M 2 359M 2 377M 2 466M 2 542M 2 462M 2 099M 2 132M 2 424M 1 609M 1 628M 1 737M 1 698M 1 655M 1 666M 1 727M 1 737M 1 644M 1 603M 1 788M 1 762M 1 701M 1 735M 1 714M 1 786M
otherExpenses 498M 507M 512M 514M 520M 504M 509M 508M 510M 553M 561M 483M 484M 483M 486M 488M 544M 562M 584M 560M 501M 392M 522M 121M 140M 145M 144M 143M 151M 151M 156M 163M 132M 161M 174M 198M 197M 197M 199M
operatingExpenses 4 011M 3 948M 3 996M 4 324M 3 959M 3 884M 3 946M 3 776M 3 392M 3 393M 3 687M 3 491M 3 520M 3 494M 3 636M 3 409M 3 495M 3 603M 3 715M 3 635M 3 162M 3 037M 3 493M 2 073M 2 120M 2 230M 2 221M 2 167M 2 195M 2 223M 2 206M 2 163M 2 042M 2 284M 2 323M 2 286M 2 288M 2 274M 2 331M
costAndExpenses 8 640M 8 881M 8 983M 9 090M 8 382M 8 831M 8 347M 8 269M 7 358M 6 656M 6 968M 6 925M 6 878M 6 773M 6 796M 6 600M 6 661M 6 885M 6 782M 6 898M 6 019M 6 210M 6 537M 4 385M 4 405M 4 517M 4 361M 4 373M 4 437M 4 441M 4 287M 4 463M 4 373M 4 790M 4 793M 4 899M 4 739M 4 819M 4 763M
interestIncome 55M 26M 14M 11M 10M 11M
interestExpense 141M 132M 131M 131M 133M 134M 135M 136M 137M 134M 139M 164M 167M 168M 171M 186M 203M 210M 227M 246M 218M 214M 226M 153M 117M 103M 58M 41M 41M 44M 37M 43M 35M 39M 39M 36M 40M 41M 41M
depreciationAndAmortization 815M 822M 823M 883M 847M 874M 934M 866M 808M 825M 828M 756M 754M 751M 753M 763M 813M 850M 852M 843M 756M 648M 774M 319M 340M 347M 347M 366M 383M 352M 371M 395M 355M 400M 398M 426M 437M 436M 421M
ebitda 2 714M 3 306M 3 830M 3 341M 3 473M 2 356M 3 112M 3 394M 2 366M 1 485M 1 620M 2 160M 2 024M 2 021M 1 556M 1 895M 1 745M 1 852M 1 519M 1 699M 1 642M 1 170M 1 769M 1 380M 306M 1 181M 667M 1 309M 1 122M 1 380M 2 824M 1 512M 1 206M 1 182M 896M 1 199M 1 298M 1 077M 1 016M
ebitdaratio 0.261 0.294 0.322 0.291 0.318 0.230 0.298 0.317 0.267 0.203 0.210 0.260 0.251 0.253 0.207 0.244 0.228 0.238 0.206 0.224 0.240 0.176 0.279 0.259 0.058 0.221 0.137 0.252 0.218 0.267 0.577 0.286 0.236 0.213 0.171 0.212 0.242 0.198 0.189
operatingIncome 1 770M 2 376M 2 912M 2 378M 2 546M 1 392M 2 109M 2 432M 1 495M 672M 758M 1 389M 1 198M 1 206M 739M 1 165M 995M 882M 608M 691M 810M 427M -202M 948M 897M 816M 524M 815M 713M 729M 610M 827M 731M 761M 451M 756M 630M 627M 615M
operatingIncomeRatio 0.170 0.211 0.245 0.207 0.233 0.132 0.195 0.227 0.169 0.092 0.098 0.167 0.148 0.151 0.098 0.150 0.130 0.114 0.082 0.091 0.119 0.064 -0.032 0.178 0.169 0.153 0.107 0.157 0.138 0.141 0.125 0.156 0.143 0.137 0.086 0.134 0.117 0.115 0.114
totalOtherIncomeExpensesNet -12M -24M -36M -51M -53M 44M 66M 44M 74M 146M 125M 149M 95M 104M 107M 218M 277M 105M 177M 117M 184M 132M -938M 73M 1 076M 101M 522M -15M -1 000 000 -257M -43M 25M 13M 24M 28M 19M 2M 27M 60M
incomeBeforeTax 1 758M 2 352M 2 876M 2 327M 2 493M 1 348M 2 043M 2 388M 1 421M 526M 633M 1 240M 1 103M 1 102M 632M 947M 718M 777M 431M 574M 626M 295M 736M 875M -179M 715M 2M 830M 714M 986M 653M 802M 718M 737M 423M 737M 628M 601M 555M
incomeBeforeTaxRatio 0.169 0.209 0.242 0.203 0.228 0.132 0.195 0.223 0.161 0.072 0.082 0.149 0.137 0.138 0.084 0.122 0.094 0.100 0.058 0.076 0.092 0.044 0.116 0.164 -0.034 0.134 0.000 0.160 0.139 0.191 0.133 0.152 0.141 0.133 0.081 0.130 0.117 0.110 0.103
incomeTaxExpense 323M 334M 429M 338M 393M 159M 250M 230M 189M -11M 89M 191M 143M 96M -40M 292M 166M 59M 22M 1 438M 65M 25M 350M 110M 178M 116M -54M 135M 118M 200M 124M 170M 278M 277M 84M 148M -144M 125M 10M
netIncome 1 435M 2 018M 2 447M 1 989M 2 100M 1 189M 1 793M 2 162M 1 232M 537M 564M 1 049M 960M 1 006M 672M 654M 563M 733M 418M -828M 603M 283M 419M 798M -329M 615M 316M 767M 580M 784M 2 292M 904M 538M 466M 375M 590M 966M 476M 545M
netIncomeRatio 0.138 0.179 0.206 0.173 0.192 0.116 0.171 0.202 0.139 0.073 0.073 0.126 0.119 0.126 0.089 0.084 0.074 0.094 0.057 -0.109 0.088 0.043 0.066 0.150 -0.062 0.115 0.065 0.148 0.113 0.152 0.468 0.171 0.105 0.084 0.072 0.104 0.180 0.087 0.101
eps 1.150 1.152 1.398 1.127 1.188 0.671 1.000 1.221 0.695 0.303 0.319 0.595 0.543 0.569 0.381 0.373 0.321 0.418 0.238 -0.475 0.346 0.163 0.241 0.542 -0.223 0.418 0.215 0.521 0.389 0.526 1.540 0.600 0.357 0.310 0.250 0.380 0.625 0.306 0.349
epsdiluted 0.810 1.140 1.370 1.110 1.170 0.660 1.000 1.200 0.690 0.300 0.310 0.590 0.530 0.560 0.380 0.370 0.320 0.410 0.230 -0.480 0.340 0.160 0.240 0.530 -0.223 0.410 0.210 0.510 0.380 0.520 1.510 0.590 0.354 0.300 0.240 0.370 0.610 0.300 0.340
weightedAverageShsOut 1 248M 1 751M 1 751M 1 764M 1 768M 1 773M 1 777M 1 771M 1 772M 1 771M 1 769M 1 763M 1 768M 1 767M 1 764M 1 756M 1 756M 1 754M 1 753M 1 744M 1 741M 1 737M 1 735M 1 473M 1 472M 1 470M 1 469M 1 473M 1 492M 1 490M 1 489M 1 508M 1 506M 1 504M 1 502M 1 548M 1 546M 1 554M 1 559M
weightedAverageShsOutDil 1 764M 1 765M 1 775M 1 782M 1 789M 1 793M 1 792M 1 789M 1 788M 1 785M 1 781M 1 781M 1 784M 1 781M 1 777M 1 774M 1 772M 1 769M 1 765M 1 746M 1 754M 1 749M 1 735M 1 483M 1 476M 1 480M 1 484M 1 498M 1 505M 1 504M 1 516M 1 522M 1 520M 1 517M 1 548M 1 567M 1 567M 1 577M 1 586M
link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2022 q3 2022 q2 2022 q1 2021 q4 2021 q3 2021 q2 2021 q1 2020 q4 2020 q3 2020 q2 2020 q1 2019 q4 2019 q3 2019 q2 2019 q1 2018 q4 2018 q3 2018 q2 2018 q1 2017 q4 2017 q3 2017 q2 2017 q1 2016 q4 2016 q3 2016 q2 2016 q1 2015 q4 2015 q3 2015 q2 2015 q1 2014 q4 2014 q3 2014 q2 2014 q1 2013 q4 2013 q3 2013 q2 2013 q1
date 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31
symbol ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1800.000 1800.000 1800.000 1800.000 1800.000 1800.000
fillingDate 2022-11-01 2022-08-02 2022-05-03 2022-02-18 2021-11-03 2021-08-04 2021-05-05 2021-02-19 2020-11-04 2020-07-29 2020-04-29 00:00:00 2020-02-21 00:00:00 2019-10-31 00:00:00 2019-07-31 2019-05-01 00:00:00 2019-02-22 00:00:00 2018-10-31 00:00:00 2018-08-01 00:00:00 2018-05-02 00:00:00 2018-02-16 00:00:00 2017-11-02 00:00:00 2017-08-02 00:00:00 2017-05-03 00:00:00 2017-02-17 00:00:00 2016-11-03 00:00:00 2016-08-03 2016-05-04 00:00:00 2016-02-19 00:00:00 2015-11-05 00:00:00 2015-08-04 00:00:00 2015-05-06 00:00:00 2015-02-27 2014-11-06 00:00:00 2014-08-05 00:00:00 2014-05-07 00:00:00 2014-02-21 2013-11-07 00:00:00 2013-08-06 00:00:00 2013-05-08 00:00:00
acceptedDate 2022-11-01 16:06:19 2022-08-02 16:02:47 2022-05-03 16:29:24 2022-02-18 16:02:57 2021-11-03 16:04:53 2021-08-04 16:01:33 2021-05-05 16:01:22 2021-02-19 16:10:04 2020-11-04 16:01:05 2020-07-29 17:16:23 2020-04-29 16:16:47 2020-02-21 16:28:23 2019-10-31 16:02:42 2019-07-31 16:15:28 2019-05-01 16:09:25 2019-02-22 16:13:21 2018-10-31 16:02:08 2018-08-01 16:02:04 2018-05-02 16:17:34 2018-02-16 16:04:37 2017-11-02 16:18:54 2017-08-02 16:16:39 2017-05-03 16:17:02 2017-02-17 16:17:24 2016-11-03 16:26:45 2016-08-03 16:32:32 2016-05-04 16:32:12 2016-02-19 15:48:41 2015-11-05 14:37:57 2015-08-04 16:28:00 2015-05-06 16:56:54 2015-02-27 12:57:49 2014-11-06 17:01:19 2014-08-05 16:32:05 2014-05-07 16:47:07 2014-02-21 17:16:35 2013-11-07 16:05:51 2013-08-06 12:33:40 2013-05-08 15:33:31
calendarYear 2022.000 2022.000 2022.000 2021.000 2021.000 2021.000
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 9 594M 8 937M 7 675M 9 799M 9 302M 8 658M 8 054M 6 838M 4 480M 4 763M 3 377M 3 860M 4 091M 3 137M 3 022M 3 844M 7 369M 3 065M 3 857M 9 407M 11 012M 9 675M 8 706M 18 620M 2 500M 2 578M 3 334M 5 001M 3 132M 4 048M 3 226M 4 063M 3 613M 3 570M 2 060M 3 475M 2 882M 5 572M 4 373M
shortTermInvestments 313M 353M 483M 450M 390M 286M 318M 310M 251M 274M 291M 280M 244M 239M 239M 242M 181M 199M 185M 203M 187M 160M 154M 155M 2 007M 1 860M 623M 1 124M 3 007M 7 129M 6 623M 397M 1 264M 3 492M 4 987M 4 623M 5 723M 3 821M 4 144M
cashAndShortTermInvestments 9 907M 9 290M 8 158M 10 249M 9 692M 8 944M 8 372M 7 148M 4 731M 5 037M 3 668M 4 140M 4 335M 3 376M 3 261M 4 086M 7 550M 3 264M 4 042M 9 610M 11 199M 9 835M 8 860M 18 775M 4 507M 4 438M 3 957M 6 125M 6 139M 11 177M 9 849M 4 460M 4 877M 7 062M 7 047M 8 098M 8 605M 9 394M 8 517M
netReceivables 6 408M 7 199M 7 179M 6 487M 8 539M 8 244M 8 058M 6 414M 7 507M 6 982M 7 262M 5 425M 7 392M 7 467M 7 063M 5 182M 6 853M 7 127M 7 076M 5 249M 6 695M 6 545M 6 474M 3 248M 5 306M 5 671M 5 587M 3 418M 6 983M 7 126M 7 340M 3 586M 7 791M 8 121M 7 860M 3 986M 7 800M 7 179M 7 332M
inventory 5 734M 5 899M 5 691M 5 157M 5 261M 5 439M 5 387M 5 012M 5 152M 5 202M 4 568M 4 316M 4 392M 4 352M 4 085M 3 796M 3 781M 3 714M 3 826M 3 601M 3 483M 3 603M 3 995M 2 434M 2 613M 2 813M 2 786M 2 599M 2 633M 2 735M 2 623M 2 643M 2 696M 2 823M 2 775M 2 693M 2 804M 2 725M 2 710M
otherCurrentAssets 2 796M 2 568M 2 401M 2 346M 0 0 0 1 867M 0 0 0 1 786M 0 0 0 1 568M 12M 17M 20M 1 687M 0 0 0 2 319M 552M 66M 76M 2 013M 139M 93M 173M 4 572M 1 100M 252M 249M 4 470M 539M 533M 537M
totalCurrentAssets 24 845M 24 956M 23 429M 24 239M 23 492M 22 627M 21 817M 20 441M 17 390M 17 221M 15 498M 15 667M 16 119M 15 195M 14 409M 14 632M 18 196M 14 122M 14 964M 20 147M 21 377M 19 983M 19 329M 26 776M 12 978M 12 988M 12 406M 14 155M 15 894M 21 131M 19 985M 15 261M 16 464M 18 258M 17 931M 19 247M 19 749M 19 831M 19 097M
propertyPlantEquipmentNet 8 689M 8 818M 8 908M 8 959M 8 831M 8 816M 8 832M 9 029M 8 620M 8 343M 7 907M 8 038M 7 825M 7 825M 7 626M 7 563M 7 448M 7 432M 7 659M 7 607M 7 219M 7 286M 7 265M 5 705M 5 734M 5 826M 5 836M 5 730M 5 797M 5 738M 5 699M 5 935M 5 872M 5 935M 5 948M 5 905M 5 842M 5 769M 5 791M
goodwill 22 284M 22 744M 23 179M 23 231M 23 299M 23 485M 23 384M 23 744M 23 338M 23 082M 22 927M 23 195M 23 046M 23 329M 23 209M 23 254M 23 416M 23 844M 24 227M 24 020M 22 066M 22 132M 21 353M 7 683M 7 812M 9 752M 9 775M 9 638M 9 750M 9 896M 9 855M 10 067M 10 048M 9 751M 9 781M 9 772M 9 724M 9 358M 9 425M
intangibleAssets 10 850M 11 592M 12 225M 12 739M 13 312M 13 681M 14 181M 14 784M 15 208M 15 800M 16 200M 17 025M 17 500M 18 091M 18 472M 18 942M 19 477M 19 951M 20 943M 21 473M 18 578M 18 653M 19 405M 4 539M 4 674M 5 311M 5 458M 5 562M 5 844M 5 785M 5 979M 6 198M 6 094M 5 428M 5 613M 5 735M 5 927M 5 643M 6 058M
goodwillAndIntangibleAssets 33 134M 34 336M 35 404M 35 970M 36 611M 37 166M 37 565M 38 528M 38 546M 38 882M 39 127M 40 220M 40 546M 41 420M 41 681M 42 196M 42 893M 43 795M 45 170M 45 493M 40 644M 40 785M 40 758M 12 222M 12 486M 15 063M 15 233M 15 200M 15 594M 15 681M 15 834M 16 265M 16 142M 15 179M 15 394M 15 507M 15 651M 15 000M 15 482M
longTermInvestments 764M 734M 763M 816M 812M 805M 832M 821M 803M 776M 790M 883M 874M 851M 867M 897M 971M 940M 913M 883M 1 386M 1 545M 1 756M 2 947M 2 997M 3 339M 3 552M 4 041M 3 055M 243M 244M 229M 221M 130M 122M 119M 143M 154M 146M
taxAssets 5 369M 5 358M 5 503M 5 212M 4 049M 3 855M 3 739M 3 729M 3 684M 3 571M 3 390M 3 079M 3 210M 3 136M 3 027M 1 868M 2 110M 2 005M 2 082M 1 944M 1 565M 1 552M 1 779M 2 263M 2 523M 2 613M 2 608M 2 119M 1 383M 1 330M 1 330M 1 651M 1 772M 1 921M 2 214M 2 109M 2 671M 2 078M 2 098M
otherNonCurrentAssets 0 0 0 0 0 0 0 0 0 -17M 0 0 -35M 0 0 17M 19M 121M 120M 176M 57M 0 0 2 753M 2 779M 2M 2M 2M 2M 2M 3M 1 934M 2 043M 52M 53M 66M 77M 71M 72M
totalNonCurrentAssets 47 956M 49 246M 50 578M 50 957M 50 303M 50 642M 50 968M 52 107M 51 653M 51 555M 51 214M 52 220M 52 420M 53 232M 53 201M 52 541M 53 441M 54 293M 55 944M 56 103M 50 871M 51 168M 51 558M 25 890M 26 519M 26 843M 27 231M 27 092M 25 831M 22 994M 23 110M 26 014M 26 050M 23 217M 23 731M 23 706M 24 384M 23 072M 23 590M
otherAssets 0 0 0 0 0 0 0 0 0 0 65M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 72 801M 74 202M 74 007M 75 196M 73 795M 73 269M 72 785M 72 548M 69 043M 68 776M 66 777M 67 887M 68 539M 68 427M 67 610M 67 173M 71 637M 68 415M 70 908M 76 250M 72 248M 71 151M 70 887M 52 666M 39 497M 39 831M 39 637M 41 247M 41 725M 44 125M 43 095M 41 275M 42 514M 41 475M 41 662M 42 953M 44 132M 42 903M 42 687M
accountPayables 4 133M 4 493M 4 757M 4 408M 4 017M 4 017M 4 066M 3 946M 3 189M 3 335M 3 181M 3 252M 3 029M 3 222M 3 045M 2 975M 2 730M 2 503M 2 476M 2 402M 1 858M 1 667M 1 481M 1 178M 1 051M 1 153M 1 053M 1 081M 1 007M 1 000M 1 012M 1 064M 965M 1 062M 1 074M 1 026M 1 009M 1 042M 1 088M
shortTermDebt 1 117M 5M 4M 754M 951M 954M 955M 220M 214M 1 495M 1 468M 1 478M 1 458M 212M 209M 207M 4 274M 847M 737M 714M 715M 221M 210M 1 325M 2 535M 2 896M 2 613M 3 130M 2 402M 2 899M 2 972M 4 437M 4 582M 3 962M 4 378M 3 173M 4 860M 4 524M 3 636M
taxPayables 394M 355M 338M 306M 368M 242M 276M 362M 117M 165M 165M 226M 67M 83M 277M 305M 231M 188M 212M 309M 180M 192M 186M 188M 240M 232M 261M 430M 483M 589M 534M 270M 481M 181M 152M 175M 228M 139M 142M
deferredRevenue 0 0 0 0 0 0 0 3 729M 3 684M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 7 721M 7 539M 7 548M 7 943M 7 899M 7 643M 7 441M 4 012M 3 170M 6 129M 6 159M 6 133M 6 004M 5 628M 5 859M 5 830M 5 772M 5 601M 5 797M 5 796M 5 362M 4 915M 4 955M 4 157M 4 735M 4 624M 4 727M 4 975M 5 346M 5 286M 5 222M 5 031M 5 276M 4 829M 4 734M 5 308M 5 463M 5 354M 5 682M
totalCurrentLiabilities 13 365M 12 392M 12 647M 13 105M 12 867M 12 614M 12 462M 11 907M 10 257M 10 959M 10 808M 10 863M 10 491M 9 062M 9 113M 9 012M 12 776M 8 951M 9 010M 8 912M 7 935M 6 803M 6 646M 6 660M 8 321M 8 673M 8 393M 9 186M 8 755M 9 185M 9 206M 10 532M 10 823M 9 853M 10 186M 9 507M 11 332M 10 920M 10 406M
longTermDebt 15 297M 16 755M 17 086M 18 252M 17 446M 17 547M 17 489M 18 527M 18 349M 18 184M 16 804M 16 661M 17 639M 18 982M 18 845M 19 359M 19 284M 19 823M 21 154M 27 210M 23 310M 23 810M 23 764M 20 681M 5 975M 6 016M 5 977M 5 871M 5 953M 5 862M 5 931M 3 408M 3 719M 3 403M 3 387M 3 388M 3 403M 3 411M 3 467M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 8 339M 0 1 392M 0 0 0 1 406M 8 842M 0 0 1 546M 0 0 0 2 056M 0 0 0 2 006M 0 0 0 356M 0 0 0 808M 0 0 0 860M 0 0 0 466M 0 0 0
otherNonCurrentLiabilities 8 255M 0 8 645M 6 423M 8 844M 9 079M 9 046M 7 705M 0 8 835M 8 738M 7 516M 8 390M 8 489M 8 523M 6 024M 8 679M 8 867M 9 143M 7 024M 8 785M 8 750M 8 930M 4 252M 4 305M 4 347M 4 425M 4 056M 5 798M 5 952M 5 970M 4 836M 4 979M 4 515M 4 600M 4 325M 5 610M 6 145M 6 130M
totalNonCurrentLiabilities 23 552M 25 094M 25 731M 26 067M 26 290M 26 626M 26 535M 27 638M 27 191M 27 019M 25 542M 25 723M 26 029M 27 471M 27 368M 27 439M 27 963M 28 690M 30 297M 36 240M 32 095M 32 560M 32 694M 25 289M 10 280M 10 363M 10 402M 10 735M 11 751M 11 814M 11 901M 9 104M 8 698M 7 918M 7 987M 8 179M 9 013M 9 556M 9 597M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 8 255M 8 339M 0 956M 0 0
totalLiabilities 36 917M 37 486M 38 378M 39 172M 39 157M 39 240M 38 997M 39 545M 37 448M 37 978M 36 350M 36 586M 36 520M 36 533M 36 481M 36 451M 40 739M 37 641M 39 307M 45 152M 40 030M 39 363M 39 340M 31 949M 18 601M 19 036M 18 795M 19 921M 20 506M 20 999M 21 107M 19 636M 19 521M 17 771M 18 173M 17 686M 20 345M 20 476M 20 003M
preferredStock 0 0 0 0 0 0
commonStock 24 560M 24 429M 24 304M 24 470M 24 285M 24 153M 24 023M 24 145M 24 037M 23 893M 23 731M 23 853M 23 771M 23 665M 23 461M 23 512M 23 428M 23 317M 23 223M 23 206M 23 118M 23 012M 22 886M 13 027M 12 939M 12 835M 12 744M 12 734M 12 641M 12 566M 12 462M 12 383M 12 207M 12 126M 12 032M 12 048M 11 793M 11 731M 11 615M
retainedEarnings 35 115M 34 487M 33 295M 31 528M 30 376M 29 053M 28 669M 27 627M 26 266M 25 669M 25 786M 25 847M 25 440M 25 045M 24 613M 24 560M 24 144M 24 080M 23 856M 23 978M 25 320M 25 202M 25 387M 25 565M 25 162M 25 884M 25 654M 25 757M 25 375M 25 162M 24 740M 22 874M 22 335M 22 137M 22 005M 21 979M 21 668M 20 319M 20 062M
accumulatedOtherComprehensiveIncomeLoss -9 445M -8 706M -8 474M -8 374M -9 240M -9 066M -9 285M -8 946M -9 044M -9 080M -9 386M -8 465M -7 763M -7 365M -7 470M -7 586M -7 009M -6 913M -5 733M -6 062M -6 116M -6 250M -6 532M -7 263M -6 533M -7 223M -6 851M -6 658M -7 211M -5 004M -5 607M -5 053M -2 975M -1 952M -1 934M -2 012M -2 957M -3 226M -2 895M
othertotalStockholdersEquity -14 555M -13 720M -13 726M -11 822M -10 999M -10 340M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalStockholdersEquity 35 675M 36 490M 35 399M 35 802M 34 422M 33 800M 33 788M 33 003M 31 595M 30 798M 30 427M 31 301M 32 019M 31 894M 31 129M 30 722M 30 898M 30 774M 31 601M 31 098M 32 218M 31 788M 31 547M 20 717M 20 896M 20 795M 20 842M 21 326M 21 219M 23 126M 21 988M 21 639M 22 993M 23 704M 23 489M 25 267M 23 788M 22 428M 22 683M
totalLiabilitiesAndStockholdersEquity 72 592M 73 976M 73 777M 74 974M 73 579M 73 040M 72 785M 72 548M 69 043M 68 776M 66 777M 67 887M 68 539M 68 427M 67 610M 67 173M 71 637M 68 415M 70 908M 76 250M 72 248M 71 151M 70 887M 52 666M 39 497M 39 831M 39 637M 41 247M 41 725M 44 125M 43 095M 41 275M 42 514M 41 475M 41 662M 42 953M 44 132M 42 903M 42 687M
minorityInterest 209M 226M 230M 222M 216M 229M
totalEquity 35 884M 36 716M 35 629M 36 024M 34 638M 34 029M
totalLiabilitiesAndTotalEquity 72 801M 74 202M 74 007M 75 196M 73 795M 73 269M
totalInvestments 1 077M 1 087M 1 246M 1 266M 1 202M 1 091M 1 150M 1 131M 1 054M 1 050M 1 081M 1 163M 1 118M 1 090M 1 106M 1 139M 1 152M 1 139M 1 098M 1 086M 1 573M 1 705M 1 910M 3 102M 5 004M 5 199M 4 175M 5 165M 6 062M 7 372M 6 867M 626M 1 485M 3 622M 5 109M 4 742M 5 866M 3 976M 4 290M
totalDebt 16 414M 16 760M 17 090M 19 006M 18 397M 18 501M 18 444M 18 747M 18 563M 19 679M 18 272M 18 139M 19 097M 19 194M 19 054M 19 566M 23 558M 20 670M 21 891M 27 924M 24 025M 24 031M 23 974M 22 006M 8 510M 8 912M 8 590M 9 001M 8 355M 8 761M 8 903M 7 845M 8 301M 7 365M 7 765M 6 561M 8 263M 7 935M 7 102M
netDebt 6 820M 7 823M 9 415M 9 207M 9 095M 9 843M 10 390M 11 909M 14 083M 14 916M 14 895M 14 279M 15 006M 16 057M 16 032M 15 722M 16 189M 17 605M 18 034M 18 517M 13 013M 14 356M 15 268M 3 386M 6 010M 6 334M 5 256M 4 000M 5 223M 4 713M 5 677M 3 782M 4 688M 3 795M 5 705M 3 086M 5 380M 2 362M 2 729M
link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2022 q3 2022 q2 2022 q1 2021 q4 2021 q3 2021 q2 2021 q1 2020 q4 2020 q3 2020 q2 2020 q1 2019 q4 2019 q3 2019 q2 2019 q1 2018 q4 2018 q3 2018 q2 2018 q1 2017 q4 2017 q3 2017 q2 2017 q1 2016 q4 2016 q3 2016 q2 2016 q1 2015 q4 2015 q3 2015 q2 2015 q1 2014 q4 2014 q3 2014 q2 2014 q1 2013 q4 2013 q3 2013 q2 2013 q1
date 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31
symbol ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT ABT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1800.000 1800.000 1800.000 1800.000 1800.000 1800.000
fillingDate 2022-11-01 2022-08-02 2022-05-03 2022-02-18 2021-11-03 2021-08-04 2021-05-05 2021-02-19 2020-11-04 2020-07-29 2020-04-29 00:00:00 2020-02-21 00:00:00 2019-10-31 00:00:00 2019-07-31 2019-05-01 00:00:00 2019-02-22 00:00:00 2018-10-31 00:00:00 2018-08-01 00:00:00 2018-05-02 00:00:00 2018-02-16 00:00:00 2017-11-02 00:00:00 2017-08-02 00:00:00 2017-05-03 00:00:00 2017-02-17 00:00:00 2016-11-03 00:00:00 2016-08-03 2016-05-04 00:00:00 2016-02-19 00:00:00 2015-11-05 00:00:00 2015-08-04 00:00:00 2015-05-06 00:00:00 2015-02-27 2014-11-06 00:00:00 2014-08-05 00:00:00 2014-05-07 00:00:00 2014-02-21 2013-11-07 00:00:00 2013-08-06 00:00:00 2013-05-08 00:00:00
acceptedDate 2022-11-01 16:06:19 2022-08-02 16:02:47 2022-05-03 16:29:24 2022-02-18 16:02:57 2021-11-03 16:04:53 2021-08-04 16:01:33 2021-05-05 16:01:22 2021-02-19 16:10:04 2020-11-04 16:01:05 2020-07-29 17:16:23 2020-04-29 16:16:47 2020-02-21 16:28:23 2019-10-31 16:02:42 2019-07-31 16:15:28 2019-05-01 16:09:25 2019-02-22 16:13:21 2018-10-31 16:02:08 2018-08-01 16:02:04 2018-05-02 16:17:34 2018-02-16 16:04:37 2017-11-02 16:18:54 2017-08-02 16:16:39 2017-05-03 16:17:02 2017-02-17 16:17:24 2016-11-03 16:26:45 2016-08-03 16:32:32 2016-05-04 16:32:12 2016-02-19 15:48:41 2015-11-05 14:37:57 2015-08-04 16:28:00 2015-05-06 16:56:54 2015-02-27 12:57:49 2014-11-06 17:01:19 2014-08-05 16:32:05 2014-05-07 16:47:07 2014-02-21 17:16:35 2013-11-07 16:05:51 2013-08-06 12:33:40 2013-05-08 15:33:31
calendarYear 2022.000 2022.000 2022.000 2021.000 2021.000 2021.000
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
netIncome 1 435M 2 018M 2 447M 1 989M 2 100M 1 189M 1 793M 2 162M 1 232M 537M 564M 1 049M 960M 1 006M 672M 654M 563M 733M 418M -828M 603M 283M 419M 798M -329M 615M 316M 767M 580M 784M 2 292M 904M 538M 466M 375M 590M 966M 476M 545M
depreciationAndAmortization 815M 822M 823M 883M 847M 874M 934M 866M 808M 825M 828M 756M 754M 751M 753M 763M 813M 850M 852M 843M 756M 648M 774M 319M 340M 347M 347M 366M 383M 352M 371M 395M 355M 400M 398M 426M 437M 436M 421M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 123M 142M 305M 106M 114M 132M 288M 98M 100M 115M 233M 85M 94M 114M 226M 81M 83M 101M 212M 68M 75M 92M 171M 47M 49M 62M 152M 43M 44M 57M 148M 38M 40M 49M 119M 40M 45M 52M 126M
changeInWorkingCapital 336M -664M -1 305M -106M -323M 30M -372M 1 401M 871M 1 572M -114M -824M -505M 837M -324M 200M 249M -783M -5 281M -2 207M 262M 497M -7 433M 15 459M 342M 302M -956M -2 170M -4 807M 1 167M 6 050M -912M -2 764M 660M -1 995M 1 323M -494M 221M -9 352M
accountsReceivables 530M -188M -751M -189M -394M 35M 165M -581M -470M 231M -104M 82M -22M -165M -170M 90M -143M -84M -53M -38M -113M -86M 30M -61M 34M -146M -4M -20M -26M -35M -90M -22M -97M -158M 82M -135M 113M -81M -10M
inventory -194M -476M -554M 15M 71M -5M -537M 345M 149M -550M -437M 137M -190M -254M -286M -64M -114M -165M -171M 210M 166M 35M -162M 54M -3M -54M -95M -44M -3M -82M -128M -94M -62M -51M -90M 88M -10M -100M -132M
accountsPayables 0 0 0 1 288M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherWorkingCapital 0 0 0 0 0 0 0 8 534M 7 133M 6 262M 4 690M 4 804M 5 628M 6 133M 5 296M 5 620M 5 420M 5 171M 5 954M 11 235M 13 442M 13 180M 12 683M 20 116M 4 657M 4 315M 4 013M 4 969M 7 139M 11 946M 10 779M 4 729M 5 641M 8 405M 7 745M 9 740M 8 417M 8 912M 8 691M
otherNonCashItems 71M 92M -205M 195M -37M -97M -6M -42M 247M 164M -369M 0 352M -392M -483M -608M 981M -191M -150M -490M 530M 379M 493M 1 166M 175M 85M -1 261M 0 234M 71M 230M 0 426M 194M -548M 0 -1 028M -66M -489M
netCashProvidedByOperatingActivities 2 780M 2 410M 2 065M 3 067M 2 701M 2 128M 2 637M 3 798M 2 066M 1 322M 715M 2 416M 1 948M 1 060M 712M 1 765M 2 183M 1 244M 1 108M 1 640M 2 005M 1 351M 574M 1 170M 1 217M 909M -93M 828M 1 195M 941M 2M 1 238M 1 201M 900M 336M 1 625M 522M 717M 460M
investmentsInPropertyPlantAndEquipment -467M -379M -321M -614M -461M -413M -397M -679M -496M -642M -360M -434M -401M -468M -335M -467M -354M -298M -275M -345M -263M -255M -272M -319M -312M -247M -243M -248M -411M -216M -235M -287M -277M -258M -255M -304M -276M -290M -274M
acquisitionsNet 0 48M 0 0 -86M 48M -15M 0 0 16M 0 1 000 000 -11M -34M -78M 0 0 48M 0 -2 829M 24M 238M -5 870M -7M -66M -7M 25M 0 -231M 2 286M 230M -495M 0 0 0 -14M -566M 0 0
purchasesOfInvestments 0 18M 0 -173M 0 0 0 -68M -15M 0 0 0 0 0 0 0 0 -37M -5M -112M -70M -13M -15M -1 841M -182M 0 0 -2 307M -570M -1 843M -213M 0 0 0 0 -6 684M -1 873M 326M -1 834M
salesMaturitiesOfInvestments 0 0 0 77M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites -17M 49M -39M 39M -104M 101M -10M 16M 39M 7M -33M -56M -20M 4M 17M -29M 31M -12M 42M 134M 3M 24M 3M 3 717M 6M -1 216M 444M 4 121M 15M 15M 13M 772M -548M 1 486M -340M 7 841M 19M 0 0
netCashUsedForInvestingActivites -484M -264M -360M -671M -651M -264M -422M -731M -472M -619M -393M -489M -432M -498M -396M -496M -323M -299M -238M -3 152M -306M -6M -6 154M 1 550M -554M -1 470M 226M 1 566M -1 197M 242M -205M -10M -825M 1 228M -595M 840M -2 697M 36M -2 108M
debtRepayment -1 000 000 -1 000 000 -751M -3M -40M -3M -2M -1 000 000 -1 330M -1 000 000 -1 000 000 -2 918M -2M -21M -500M -4 154M -999M -1 301M -5 979M -6 142M -1 000 000 -2M -2 505M -1 000 000 -1 000 000 -3M -7M -21M -3M -23M -10M 0 0 0 0 -303M 0 0 0
commonStockIssued 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStockRepurchased -798M -5M -2 307M -974M -579M -471M -275M -161M -2M -4M -236M -496M -1 000 000 -4M -217M -104M -3M -3M -128M -721M -8M -3M -95M 0 -2M -1 000 000 -519M -888M -2M -1 000 000 -1 346M -1 000 000 -1 000 000 -1 000 000 -2 192M -39M -351M -290M -925M
dividendsPaid -826M -828M -832M -798M -801M -803M -800M -641M -639M -642M -638M -568M -569M -568M -565M -495M -494M -494M -491M -464M -463M -462M -460M -386M -384M -384M -385M -360M -359M -360M -364M -335M -331M -333M -343M -218M -220M -221M -224M
otherFinancingActivites 82M 21M 67M -111M 43M 13M 110M 16M 56M 1 305M 140M 1 797M 59M 144M 140M -23M 3 967M 167M 143M 7 215M 86M 83M -1 339M 13 891M -359M 209M -521M 772M -451M 10M 1 170M -364M 61M -285M 1 383M -1 309M 12M 975M -3 584M
netCashUsedProvidedByFinancingActivities -1 543M -813M -3 823M -1 886M -1 377M -1 264M -967M -787M -1 915M 658M -735M -2 185M -513M -449M -1 142M -4 776M 2 471M -1 631M -6 455M -112M -386M -384M -4 399M 13 504M -746M -179M -1 432M -497M -815M -374M -550M -700M -271M -619M -1 152M -1 869M -559M 465M -4 733M
effectOfForexChangesOnCash -96M -71M -6M -13M -29M 4M -32M 78M 38M 25M -70M 27M -49M 2M 4M -18M -27M -106M 35M 19M 24M 8M 65M -104M 5M -16M -368M -28M -99M 13M -84M -78M -62M 1 000 000 -4M -3M 44M -18M -49M
netChangeInCash 657M 1 262M -2 124M 497M 644M 604M 1 216M 2 358M -283M 1 386M -483M -231M 954M 115M -822M -3 525M 4 304M -792M -5 550M -1 605M 1 337M 969M -9 914M 16 120M -78M -756M -1 667M 1 869M -916M 822M -837M 450M 43M 1 510M -1 415M 593M -2 690M 1 199M -6 429M
cashAtEndOfPeriod 9 594M 8 937M 7 675M 9 799M 9 302M 8 658M 8 054M 6 838M 4 480M 4 763M 3 377M 3 860M 4 091M 3 137M 3 022M 3 844M 7 369M 3 065M 3 857M 9 407M 11 012M 9 675M 8 706M 18 620M 2 500M 2 578M 3 334M 5 001M 3 132M 4 048M 3 226M 4 063M 3 613M 3 570M 2 060M 3 475M 2 882M 5 572M 4 373M
cashAtBeginningOfPeriod 8 937M 7 675M 9 799M 9 302M 8 658M 8 054M 6 838M 4 480M 4 763M 3 377M 3 860M 4 091M 3 137M 3 022M 3 844M 7 369M 3 065M 3 857M 9 407M 11 012M 9 675M 8 706M 18 620M 2 500M 2 578M 3 334M 5 001M 3 132M 4 048M 3 226M 4 063M 3 613M 3 570M 2 060M 3 475M 2 882M 5 572M 4 373M 10 802M
operatingCashFlow 2 780M 2 410M 2 065M 3 067M 2 701M 2 128M 2 637M 3 798M 2 066M 1 322M 715M 2 416M 1 948M 1 060M 712M 1 765M 2 183M 1 244M 1 108M 1 640M 2 005M 1 351M 574M 1 170M 1 217M 909M -93M 828M 1 195M 941M 2M 1 238M 1 201M 900M 336M 1 625M 522M 717M 460M
capitalExpenditure -467M -379M -321M -614M -461M -413M -397M -679M -1 498M -642M -360M -434M -401M -468M -335M -467M -354M -298M -275M -345M -263M -255M -272M -319M -312M -247M -243M -248M -411M -216M -235M -287M -277M -258M -255M -304M -276M -290M -274M
freeCashFlow 2 313M 2 031M 1 744M 2 453M 2 240M 1 715M 2 240M 3 119M 1 570M 680M 355M 1 982M 1 547M 592M 377M 1 298M 1 829M 946M 833M 1 295M 1 742M 1 096M 302M 851M 905M 662M -336M 580M 784M 725M -233M 951M 924M 642M 81M 1 321M 246M 426M 186M
link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link Link

Statements

Q Earning call transcript Income Statement Balance Sheet Statement Cash Flow Statement
2022 q3 2022-10-19
(fiscal 2022 q3)
2022-11-01 2022-11-01 2022-11-01
2022 q2 2022-07-20
(fiscal 2022 q2)
2022-06-30 2022-08-02 2022-08-02
2022 q1 2022-04-20
(fiscal 2022 q1)
2022-03-31 2022-03-31 2022-03-31
2021 q4 2022-01-26
(fiscal 2021 q4)
2021-12-31 2022-02-18 2021-12-31
2021 q3 2021-10-20
(fiscal 2021 q3)
2021-09-30 2021-11-03 2021-11-03
2021 q2 2021-07-22
(fiscal 2021 q2)
2021-08-04 2021-08-04 2021-08-04
2021 q1 2021-05-05 2021-05-05 2021-05-05
2020 q4 2021-01-27
(fiscal 2020 q4)
2021-02-19 2021-02-19 2021-02-19
2020 q3 2020-10-21
(fiscal 2020 q3)
2020-11-04 2020-11-04 2020-11-04
2020 q2 2020-07-16
(fiscal 2020 q2)
2020-07-29 2020-07-29 2020-07-29
2020 q1 2020-04-16
(fiscal 2020 q1)
2020-04-29 2020-04-29 2020-04-29
2019 q4 2020-01-22
(fiscal 2019 q4)
2020-02-21 2020-02-21 2020-02-21
2019 q3 2019-10-16
(fiscal 2019 q3)
2019-10-31 2019-10-31 2019-10-31
2019 q2 2019-07-17
(fiscal 2019 q2)
2019-07-31 2019-07-31 2019-07-31
2019 q1 2019-04-17
(fiscal 2019 q1)
2019-05-01 2019-05-01 2019-05-01
2018 q4 2019-01-23
(fiscal 2018 q4)
2019-02-22 2019-02-22 2019-02-22
2018 q3 2018-10-17
(fiscal 2018 q3)
2018-10-31 2018-10-31 2018-10-31
2018 q2 2018-07-18
(fiscal 2018 q2)
2018-08-01 2018-08-01 2018-08-01
2018 q1 2018-04-18
(fiscal 2018 q1)
2018-05-02 2018-05-02 2018-05-02
2017 q4 2018-01-24
(fiscal 2017 q4)
2018-02-16 2018-02-16 2018-02-16
2017 q3 2017-10-18
(fiscal 2017 q3)
2017-11-02 2017-11-02 2017-11-02
2017 q2 2017-07-20
(fiscal 2017 q2)
2017-08-02 2017-08-02 2017-08-02
2017 q1 2017-04-19
(fiscal 2017 q1)
2017-05-03 2017-05-03 2017-05-03
2016 q4 2017-01-25
(fiscal 2016 q4)
2017-02-17 2017-02-17 2017-02-17
2016 q3 2016-10-19
(fiscal 2016 q3)
2016-11-03 2016-11-03 2016-11-03
2016 q2 2016-07-20
(fiscal 2016 q2)
2016-08-03 2016-08-03 2016-08-03
2016 q1 2016-04-20
(fiscal 2016 q1)
2016-05-04 2016-05-04 2016-05-04
2015 q4 2016-01-28
(fiscal 2015 q4)
2016-02-19 2016-02-19 2016-02-19
2015 q3 2015-10-21
(fiscal 2015 q3)
2015-11-05 2015-11-05 2015-11-05
2015 q2 2015-07-22
(fiscal 2015 q2)
2015-08-04 2015-08-04 2015-08-04
2015 q1 2015-04-22
(fiscal 2015 q1)
2015-05-06 2015-05-06 2015-05-06
2014 q4 2015-01-29
(fiscal 2014 q4)
2015-02-27 2015-02-27 2015-02-27
2014 q3 2014-10-22
(fiscal 2014 q3)
2014-11-06 2014-11-06 2014-11-06
2014 q2 2014-07-16
(fiscal 2014 q2)
2014-08-05 2014-08-05 2014-08-05
2014 q1 2014-04-16
(fiscal 2014 q1)
2014-05-07 2014-05-07 2014-05-07
2013 q4 2014-01-22
(fiscal 2013 q4)
2014-02-21 2014-02-21 2014-02-21
2013 q3 2013-10-16
(fiscal 2013 q3)
2013-11-07 2013-11-07 2013-11-07
2013 q2 2013-07-17
(fiscal 2013 q2)
2013-08-06 2013-08-06 2013-08-06
2013 q1 2013-04-17
(fiscal 2013 q1)
2013-05-08 2013-05-08 2013-05-08

Press-releases

Show financial reports only

2022-10-19 07:30 ET
Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance
2022-10-12 09:42 ET
Abbott and The Home Edit Redesign the Medicine Cabinet to Help People Prepare for the Upcoming Virus Season
2022-10-06 09:00 ET
New Study Published in The New England Journal of Medicine Demonstrates Abbotts FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life
2022-09-28 09:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2022-09-17 14:45 ET
Late-Breaking Data Show Breadth of Abbotts Minimally Invasive Structural Heart Technologies
2022-07-20 07:30 ET
Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance
2022-07-12 09:00 ET
Abbott Receives FDAs Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression
2022-06-29 09:00 ET
Abbott Hosts Conference Call for Second-Quarter Earnings
2022-06-10 11:26 ET
Abbott Declares 394th Consecutive Quarterly Dividend
2022-06-05 09:00 ET
Late-Breaking Data Demonstrate Abbotts FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor
2022-04-29 09:00 ET
Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbotts Ablation Device Remain Symptom-Free for at Least 15 Months
2022-04-28 09:00 ET
Abbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer™ Steerable Delivery Sheath for the Companys Amulet™ Device
2022-04-28 07:00 ET
New Analysis Shows that Abbotts FreeStyle Libre® System Provides Similar and Sustained Reductions in Glucose Levels for People with Both Type 1 and Type 2 Diabetes
2022-04-27 08:00 ET
Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes
2022-04-26 09:00 ET
Abbott Recommends Rejection of Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
2022-04-25 09:00 ET
Abbott Strengthens Its Connected Care Technologies with Latest NeuroSphere™ myPath™ Digital Health App
2022-04-20 07:30 ET
Abbott Reports First-Quarter 2022 Results
2022-04-04 09:00 ET
Abbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms
2022-03-30 07:30 ET
Abbott and LISC Team Up to Address Diversity and Equity Gaps in the Healthcare Industry Supply Chain
2022-03-28 09:00 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2022-03-24 09:00 ET
Abbotts FreeStyle® Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin
2022-01-26 07:30 ET
Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast
2022-01-12 09:00 ET
Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms
2022-01-11 07:45 ET
ACELYRIN Appoints Melanie Gloria as Chief Operating Officer
2022-01-06 13:15 ET
Abbott Announces Future of Biowearables at Consumer Electronics Show
2021-12-10 14:00 ET
Abbott Names Robert B. Ford Chairman of the Board; Miles D. White to Retire as Executive Chairman
2021-12-10 13:00 ET
Abbott Increases Quarterly Dividend for 50th Consecutive Year
2021-11-16 13:00 ET
Abbott Launches Similac® 360 Total Care® with Exclusive Blend of Five HMO Prebiotics and Designed to Support the Immune System, Digestive Health and Brain Development
2021-11-15 10:48 ET
Abbott Achieves Highest Score in Its Industry for the Ninth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
2021-11-12 09:00 ET
Abbotts New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial
2021-11-09 09:00 ET
Abbott and the American Diabetes Association® Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology
2021-11-03 09:00 ET
Abbott Launches New Initiative to Drive Diversity in Medical Research and Improve Care Among Under-Represented Populations
2021-10-20 07:30 ET
Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
2021-10-18 09:22 ET
Jason Sudeikis Joins Abbott, Real Madrid at New York Stock Exchange to Support Childrens Health
2021-10-18 07:00 ET
Abbott and Real Madrid Team Up to Support the Health and Nutrition of Children Globally
2021-09-30 09:48 ET
Abbott Commits to Reducing Malnutrition Globally with Launch of Abbott Center for Malnutrition Solutions
2021-09-23 09:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2021-09-20 09:00 ET
Abbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease
2021-09-15 12:46 ET
Abbott Declares 391st Consecutive Quarterly Dividend
2021-09-02 09:30 ET
Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
2021-08-30 11:55 ET
Late-Breaking Data Shows Abbotts Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke
2021-08-27 08:46 ET
GUIDE-HF Study Data Show Abbotts CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure
2021-08-18 10:46 ET
Podcast: How to Find STEM Success? Learn to Pivot.
2021-08-16 12:06 ET
Strengthening Resilience in Vulnerable Communities
2021-08-16 08:00 ET
Abbotts Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
2021-08-13 09:51 ET
Abbotts Freestyle® Libre 2 IOS App Cleared In U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management
2021-08-09 08:01 ET
A Workplace Where Collaboration = Innovation
2021-08-06 08:26 ET
A Convergence of Challenges: Addressing the Devastating Impact of Chronic Disease on Communities in Crisis
2021-08-04 10:11 ET
Broader Access is Vital to the Future of Testing and Healthcare Innovation
2021-08-03 09:00 ET
Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
2021-08-02 09:00 ET
Abbotts FreeStyle® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management
2021-07-29 09:00 ET
New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations
2021-07-23 11:42 ET
Building Trust and Improving Care in Underserved Communities
2021-07-22 07:15 ET
Abbott Reports Second-Quarter 2021 Results
2021-07-15 09:16 ET
Delivering Long-Term Impact: Abbotts 2020 Sustainability Report
2021-06-30 09:00 ET
Abbotts XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
2021-06-25 11:30 ET
Late-Breaking Data Demonstrate Abbotts FreeStyle® Libre System Supports Health Equity for Millions of Americans Living with Diabetes
2021-06-25 09:00 ET
Abbott Hosts Conference Call for Second-Quarter Earnings
2021-06-24 09:00 ET
People Who Exercise Intensely Could Improve Recovery by Adjusting Their Hydration Habits
2021-06-23 08:11 ET
Abbott Earns First-of-Its-Kind Recommendation for High School STEM Interns to Receive College Credit
2021-06-22 07:00 ET
Abbott Earns First-of-its-Kind Recommendation for High School STEM Interns to Receive College Credit
2021-06-11 11:19 ET
Abbott Declares 390th Consecutive Quarterly Dividend
2021-06-03 07:00 ET
Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump
2021-06-01 08:00 ET
Abbott Issues Updated 2021 Outlook
2021-05-17 09:00 ET
Abbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis
2021-05-06 09:00 ET
Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
2021-04-20 07:30 ET
Abbott Reports First-Quarter 2021 Results
2021-04-19 08:30 ET
Abbott Begins Shipping BinaxNOW™ COVID-19 Ag Self Test to Retailers Today
2021-04-12 08:00 ET
Worlds Fastest Marathoner Eliud Kipchoge Uses Abbotts Libre Sense at NN Mission Marathon Qualifier Race for the Olympic Games
2021-04-08 09:00 ET
Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair
2021-04-06 09:00 ET
Abbotts XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients
2021-03-31 23:06 ET
Abbotts BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use
2021-03-29 10:30 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2021-03-11 09:00 ET
Abbott Announces its Pandemic Defense Coalition: A Global Network of Expert Collaborators Designed To Help Prevent Future Pandemics, Currently Searching for COVID-19 Variants
2021-03-08 09:00 ET
Abbott Introduces NeuroSphere™ Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S.
2021-03-05 09:00 ET
Abbott Receives FDA EUA for Laboratory PCR Assay That Detects and Differentiates SARS-CoV-2, Flu A, Flu B and RSV in One Test - and FDA EUA for Asymptomatic Usage of Alinity m COVID-19 Test
2021-03-02 07:45 ET
Abbott Researchers Find Rare Group of People With Controlled HIV Who Could Be a Key To Unlocking Cure
2021-02-19 13:26 ET
Abbott Declares 389th Consecutive Quarterly Dividend
2021-01-27 07:30 ET
Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021
2021-01-26 07:45 ET
Abbotts Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab
2021-01-20 07:45 ET
Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device
2021-01-14 09:00 ET
Abbott to Launch the NeuroSphere™ myPath™ Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant
2021-01-12 09:00 ET
Abbott Announces Fulfillment of Federal Government Purchase of 150 Million BinaxNOW™ COVID-19 Rapid Tests and Is Now Ready to Support Commercial Distribution
2021-01-11 09:00 ET
Abbott Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test for Concussions
2021-01-06 09:00 ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
2020-12-22 09:00 ET
As Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner
2020-12-18 09:00 ET
Abbott to Present at J.P. Morgan Healthcare Conference
2020-12-17 16:52 ET
FDA Approves Labeling Update for Abbotts HeartMate 3 Heart Pump for use in Pediatric Patients
2020-12-16 12:55 ET
Abbotts BinaxNOW COVID-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-Home Rapid Test Using eMeds Digital Health Platform
2020-12-15 09:00 ET
Abbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test
2020-12-14 09:00 ET
Abbott Develops New Pedialyte® Hydration Solution to Help Support Immune Health
2020-12-11 11:00 ET
Abbott Increases Quarterly Dividend by 25%
2020-11-18 09:00 ET
Abbott Becomes First Anchor Sponsor of American Diabetes Associations Health Equity Now Initiative to Advance Access to Care and Technology for People with Diabetes
2020-11-16 10:20 ET
Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI)
2020-11-10 09:00 ET
Abbott Announces the U.S. Launch of the IonicRF™ Generator for Use in Patients Living With Chronic Pain
2020-10-30 09:00 ET
Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device
2020-10-21 07:30 ET
Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
2020-10-19 07:15 ET
Improved Mental and Physical Condition is Directly Linked to Nutrition, Study Shows
2020-10-12 09:00 ET
Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test
2020-10-07 08:00 ET
Abbott Releases ID NOW™ COVID-19 Interim Clinical Study Results from 1,003 People to Provide the Facts on Clinical Performance and to Support Public Health
2020-10-05 16:01 ET
Quanterix Enters into a License Agreement that Grants Abbott Access to Portfolio of Bead-Based Technology Patents for Use in In Vitro Diagnostics
2020-09-28 09:00 ET
Abbotts FreeStyle® Libre 3 System Receives CE Mark - Features Worlds Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes
2020-09-21 09:02 ET
Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation
2020-09-21 09:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2020-09-17 11:39 ET
Abbott Declares 387th Consecutive Quarterly Dividend
2020-09-17 09:00 ET
Abbott Introduces Libre Sense Glucose Sport Biosensor in Europe, Worlds First Glucose Biosensor Designed for Athletes
2020-09-03 09:00 ET
Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold
2020-09-01 09:00 ET
Abbotts FreeStyle® Libre 2 iCGM System Now Available to Medicare Beneficiaries
2020-08-26 18:30 ET
Abbotts Fast, $5, 15-Minute, Easy-to-Use COVID-19 Antigen Test Receives FDA Emergency Use Authorization; Mobile App Displays Test Results to Help Our Return to Daily Life; Ramping Production to 50 Million Tests a Month
2020-08-04 09:00 ET
Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
2020-07-23 09:00 ET
Abbott Receives FDA Approval for iOS-Compatible App Allowing People Living With Chronic Pain and Movement Disorders to Personalize Therapy Via Their Mobile Device
2020-07-16 07:30 ET
Abbott Reports Second-Quarter 2020 Results, Exceeds Analysts Expectations
2020-07-13 16:15 ET
Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences
2020-07-06 07:30 ET
Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring
2020-01-13 09:00 ET
Abbott to Initiate Trial to Study MitraClip as an Option for Moderate Surgical Risk Patients
2020-01-07 10:04 ET
FDA Approves Less Invasive Surgical Approach for Abbotts Heart Pump to Help Patients Avoid Open Heart Surgery
2019-12-13 10:39 ET
Abbott Raises Quarterly Dividend 12.5%, Increasing Payouts for 48 Straight Years
2019-11-13 07:45 ET
Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020
2019-11-06 08:37 ET
Abbott Announces Discovery of New Strain of HIV, Keeping Global Health Community a Step Ahead of the Virus
2019-10-21 09:00 ET
The Australian Red Cross Blood Service Selects Abbotts Alinity s Solution for Blood and Plasma Screening
2019-04-11 15:16 ET
Abbott and the Abbott Fund Support Relief Efforts for Cyclone Idai
2019-03-20 09:00 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2019-03-19 08:00 ET
Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients

SEC forms

Show financial reports only

SEC form 10
2022-11-01 00:00 ET
Abbott published news for 2022 q3
SEC form 8
2022-10-19 07:58 ET
Abbott published news for 2022 q3
SEC form 10
2022-08-02 16:02 ET
Abbott reported for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Abbott reported for 2022 q2
SEC form 8
2022-07-20 07:36 ET
Abbott reported for 2022 q2
SEC form 10
2022-05-03 16:29 ET
Abbott reported for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Abbott reported for 2022 q1
SEC form 8
2022-04-20 07:37 ET
Abbott reported for 2022 q1
SEC form 10
2022-02-18 16:02 ET
Abbott published news for 2021 q4
SEC form 10
2022-02-18 00:00 ET
Abbott published news for 2021 q4
SEC form 8
2022-01-26 07:47 ET
Abbott published news for 2021 q4
SEC form 10
2021-11-03 16:04 ET
Abbott published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
Abbott published news for 2021 q3
SEC form 8
2021-10-20 07:47 ET
Abbott published news for 2021 q3
SEC form 10
2021-08-04 16:01 ET
Abbott published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Abbott published news for 2021 q2
SEC form 8
2021-07-22 07:22 ET
Abbott published news for 2021 q2
SEC form 10
2021-05-05 16:01 ET
Abbott published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Abbott published news for 2021 q1
SEC form 8
2021-04-20 07:38 ET
Abbott published news for 2021 q1
SEC form 10
2021-02-19 16:10 ET
Abbott published news for 2020 q4
SEC form 10
2021-02-19 00:00 ET
Abbott published news for 2020 q4
SEC form 8
2021-01-27 07:41 ET
Abbott published news for 2020 q4
SEC form 10
2020-11-04 16:01 ET
Abbott published news for 2020 q3
SEC form 8
2020-10-21 07:35 ET
Abbott published news for 2020 q3
SEC form 10
2020-07-29 17:16 ET
Abbott published news for 2020 q2
SEC form 8
2020-07-16 07:41 ET
Abbott published news for 2020 q2
SEC form 10
2020-04-29 16:16 ET
Abbott published news for 2020 q1
SEC form 8
2020-04-16 07:43 ET
Abbott published news for 2020 q1
SEC form 10
2020-02-21 16:28 ET
Abbott published news for 2019 q4
SEC form 8
2020-01-22 07:49 ET
Abbott published news for 2019 q4
SEC form 10
2019-10-31 16:02 ET
Abbott published news for 2019 q3
SEC form 8
2019-10-16 07:38 ET
Abbott published news for 2019 q3
SEC form 10
2019-07-31 16:15 ET
Abbott published news for 2019 q2
SEC form 8
2019-07-17 07:37 ET
Abbott published news for 2019 q2
SEC form 10
2019-05-01 16:09 ET
Abbott published news for 2019 q1
SEC form 8
2019-04-17 07:50 ET
Abbott published news for 2019 q1
SEC form 10
2019-02-22 16:13 ET
Abbott published news for 2018 q4
SEC form 8
2019-01-23 07:52 ET
Abbott published news for 2018 q4
SEC form 10
2018-10-31 16:02 ET
Abbott published news for 2018 q3
SEC form 8
2018-10-17 07:54 ET
Abbott published news for 2018 q3
SEC form 10
2018-08-01 16:02 ET
Abbott published news for 2018 q2
SEC form 8
2018-07-18 07:49 ET
Abbott published news for 2018 q2